Madrigal Pharmaceuticals Inc is committed to delivering innovative solutions to fight cardiovascular and metabolic diseases. The company's corporate philosophy revolves around prioritizing patient health and improving their quality of life. Madrigal Pharmaceuticals aims to develop and bring to market novel therapies that address unmet medical needs worldwide. By leveraging their expertise in lipid and liver biology, the company focuses on developing drugs that target NASH (nonalcoholic steatohepatitis) and related liver diseases. Through dedicated research, Madrigal Pharmaceuticals strives to create significant value for patients, healthcare providers, and shareholders alike.

Madrigal Pharmaceuticals Inc is primarily present in the United States.

Madrigal Pharmaceuticals Inc. has achieved several significant milestones. Firstly, the company successfully completed a Phase 2 clinical trial for its lead drug candidate, MGL-3196, showing promising results in treating non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Additionally, Madrigal Pharmaceuticals obtained Fast Track designation from the U.S. FDA for MGL-3196, highlighting its potential to address unmet medical needs. Furthermore, the company secured a worldwide license agreement with Synta Pharmaceuticals Corp., strengthening its intellectual property portfolio. Madrigal Pharmaceuticals' dedication to developing innovative therapies for metabolic and cardiovascular diseases reflects its commitment to making a profound impact in the pharmaceutical industry.

Madrigal Pharmaceuticals Inc, founded in 2011, is a clinical-stage biopharmaceutical company specializing in the development of novel, small-molecule drugs for the treatment of cardiovascular and metabolic diseases. Headquartered in West Conshohocken, Pennsylvania, the company has built a strong reputation for its innovative approach to drug discovery. Madrigal's flagship product, MGL-3196, aims to treat non-alcoholic steatohepatitis (NASH), a progressive liver disease. It has shown promising Phase 2 trial results, demonstrating significant reductions in liver fat and key metabolic markers. Madrigal Pharmaceuticals has attracted attention from investors for its focused pipeline and commitment to delivering safe and effective therapies for patients with unmet medical needs.

The main competitors of Madrigal Pharmaceuticals Inc in the market are Intercept Pharmaceuticals Inc, Viking Therapeutics Inc, and CymaBay Therapeutics Inc.

Madrigal Pharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for cardiovascular, metabolic, and liver diseases. The company's business model revolves around identifying and advancing potential drug candidates through rigorous research and clinical trials. Madrigal aims to address unmet medical needs by leveraging its expertise in lipid and liver biology. The company also seeks to pursue strategic collaborations and partnerships to further enhance its pipeline and bring novel treatments to patients.

Madrigal Pharmaceuticals KGV ir -6,45.

Madrigal Pharmaceuticals KUV ir 38,57.

AlleAktien kvalitātes vērtējums Madrigal Pharmaceuticals ir 3/10.

gaidāmā Madrigal Pharmaceuticals apgrozījums ir 102,83 milj. USD.

gaidāmā Madrigal Pharmaceuticals peļņa ir -614,71 milj. USD.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on developing innovative therapies for metabolic disorders. The company is headquartered in Conshohocken, Pennsylvania and offers a wide range of therapeutic products. The development of Madrigal Pharmaceuticals is characterized by a unique business model that emphasizes high standards in research and development, clinical trials, and marketing. The company collaborates closely with leading scientists, research institutes, and clinicians to produce products that provide effective solutions for patients with various metabolic disorders. The company's different divisions include the area of Non-Alcoholic Fatty Liver Disease (NAFLD), an increasing metabolic disorder characterized by the accumulation of fats in the liver. Madrigal Pharmaceuticals offers several products in this field, including MGL-3196, a drug that has already been approved by the FDA and is considered promising in combating NAFLD and Non-Alcoholic Steatohepatitis (NASH). Another focus of the company is in the area of atherosclerosis, a disease that leads to the hardening and narrowing of arteries. Here, the company offers its next promising drug candidates, including MGL-3745, which has shown effectiveness in lowering LDL cholesterol levels and reducing inflammation in preclinical studies. Madrigal Pharmaceuticals also relies on an innovative business model to optimize product positioning and marketing. The company has collaborative agreements with other bio-pharmaceutical companies to help spread the products and services of Madrigal Pharmaceuticals. To finance the ongoing development of therapies, Madrigal Pharmaceuticals continuously seeks investments in the form of venture capital, public financing rounds, and other financial instruments. The company has a stable network of investors and partners who support the company in achieving its mission. In summary, the business model of Madrigal Pharmaceuticals Inc is highly innovative and focused on the development of therapies for various metabolic disorders such as NAFLD and atherosclerosis. The company relies on close collaboration with pharmaceutical partners, public investments, and a strong network of researchers and scientists. This allows Madrigal Pharmaceuticals to produce products that provide effective solutions for patients with these serious conditions.

Madrigal Pharmaceuticals izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Madrigal Pharmaceuticals vai uzņēmums nedod dividendes.

Madrigal Pharmaceuticals ISIN ir US5588681057.

Madrigal Pharmaceuticals WKN ir A2APCZ.

Madrigal Pharmaceuticals simbols ir MDGL.

Pēdējo 12 mēnešu laikā Madrigal Pharmaceuticals maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Madrigal Pharmaceuticals plāno maksāt dividendes 0 USD apmērā.

Madrigal Pharmaceuticals pašreizējā dividendu rentabilitāte ir .

Madrigal Pharmaceuticals maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Madrigal Pharmaceuticals pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Madrigal Pharmaceuticals tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Madrigal Pharmaceuticals apmērā 0 USD, kas tika izmaksāta 1.10.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 1.10.2024..

Pēdējās dividendes izmaksa notika 1.10.2024..

Gadā 2023, Madrigal Pharmaceuticals izmaksāja 0 USD dividendes.

Madrigal Pharmaceuticals dividendes tiek izmaksātas USD.